Drug resistance to rituximab or cyclophosphamide.
- Caroline Holm Nørgaard (4919392)
- Lasse Hjort Jakobsen (3193176)
- Andrew J. Gentles (224554)
- Karen Dybkær (687103)
- Tarec Christoffer El-Galaly (2851736)
- Julie Støve Bødker (798590)
- Alexander Schmitz (222922)
- Preben Johansen (811305)
- Tobias Herold (532230)
- Karsten Spiekermann (532234)
- Jennifer R. Brown (228154)
- Josephine L. Klitgaard (4919389)
- Hans Erik Johnsen (687108)
- Martin Bøgsted (116784)
Publication date
March 2018
DOIAbstract
<p>Box plots represent the estimated probability of resistance to (<b>a</b>) Rituximab in normal B-cell subsets, (<b>b</b>) Rituximab in all CLL samples, (<b>c</b>) Cyclophosphamide in normal B-cell subsets and (<b>d</b>) Cyclophosphamide in all CLL samples. The global <i>P</i>-value for equal mean resistance probability was < 0.001 in all four cases. Color codes as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0193249#pone.0193249.g001" target="_blank">Fig 1</a>.</p
Add to ORKG